The review covers the combination therapy for the adjuvant treatment
of patients with stage III melanoma with BRAF V600E or V600K
mutations following complete resection.
In October, the FDA also granted breakthrough therapy designation to
Tafinlar in combination with Mekinist for the adjuvant treatment of
patients with stage III melanoma with a BRAF V600 mutation following
complete resection, the company said in a statement.
(Reporting by Michael Shields; Editing by Vyas Mohan)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |